ABPI ‘deeply concerned’ by slow UK drugs uptake
September 7, 2015Sales and Marketing ABPI, PPRS, Pharmaceutical Price Regulation Scheme, drugs bill, market access, medicines bill
The UK pharma industry paid £209 million to underwrite the UK medicines bill in second quarter of 2015, according to …
NICE recommends Keytruda for advanced skin cancer
September 7, 2015Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer
NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS. …
Pharma industry to deliver strong growth – despite price pressure
September 7, 2015Sales and Marketing Moody's, financial ratings, industry, industry growth, pharma, pharma industry
The global pharma industry will buck the trend of growing pricing pressure and deliver strong growth in profits, according to a …
Neurology comes to the fore
September 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology
Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …
Celgene threatens to scale back UK clinical trial investment after CDF snub
September 4, 2015Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs
One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …
Pfizer completes $15 billion Hospira acquisition
September 4, 2015Biosimilar Drugs, Hospira, Pfizer, mergers and acquisitions
Pfizer has completed its acquisition of Illinois-based injectable drugs and infusion device specialist Hospira for around $15 billion.The deal, first announced …
Genentech Haemophilia therapy gets FDA breakthrough designation
September 4, 2015Research and Development, Sales and Marketing Genentech, Roche, haemophilia a
Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
Companies braced for new round of cancer cuts
September 4, 2015Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts
Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …
Novartis blood cancer drug Farydak receives EU approval
September 4, 2015Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat
The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
Health ministers vow NHS tech revolution
September 3, 2015Medical Communications Jeremy Hunt, NHS, data protection, digital technology, george freeman
UK health ministers have challenged the NHS to fully utilise technology, to empower patients to manage their own healthcare needs.Their …
How ‘deep reading’ of the scientific literature will benefit pharma
September 3, 2015Research and Development Big Data, Cancer, Data Mining, R&D, literature search, oncology
The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …
NICE pushes biosimilars in rheumatoid arthritis guidance
September 3, 2015Sales and Marketing
NICE has published final draft guidance confirming its recommended treatment options for rheumatoid arthritis. For the first time copycat, or …
Sandoz launches first US biosimilar
September 3, 2015Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim
Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …
Shire appoints Sara Mathew to board of directors
September 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire
Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …
Pharma ‘spends €40m to sway EU politicians’
September 2, 2015Medical Communications EU, European Commission, TTIP, drug policy, lobbying, transparency
The pharma industry has excessive power over EU decision-makers and spends €40 million a year to influence EU drug policy, …
Amgen and Novartis partner on Alzheimer’s and migraine treatments
September 2, 2015Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience
Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine. The companies plan …
Two Novartis drugs get first in class EU approvals
September 2, 2015Research and Development, Sales and Marketing Novartis
The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …
Bayer backs safety of Xarelto after real-world data study
September 2, 2015Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban
Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
